MA38099A1 - Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4 - Google Patents

Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4

Info

Publication number
MA38099A1
MA38099A1 MA38099A MA38099A MA38099A1 MA 38099 A1 MA38099 A1 MA 38099A1 MA 38099 A MA38099 A MA 38099A MA 38099 A MA38099 A MA 38099A MA 38099 A1 MA38099 A1 MA 38099A1
Authority
MA
Morocco
Prior art keywords
triazolopyrazines
substituted
new compounds
brd4 inhibitors
compounds
Prior art date
Application number
MA38099A
Other languages
English (en)
Other versions
MA38099B1 (fr
Inventor
Harald Engelhardt
Christian Smethurst
Davide Gianni
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA38099A1 publication Critical patent/MA38099A1/fr
Publication of MA38099B1 publication Critical patent/MA38099B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/49—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton
    • C07C211/50—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton with at least two amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule générale (i), les groupes r1 à r3 ayant les significations données dans les revendications et dans la description. Les composés de l'invention sont appropriés pour le traitement de maladies caractérisées par la prolifération cellulaire excessive ou anormale, des préparations pharmaceutiques contenant de tels composés et leurs utilisations en tant que médicament.
MA38099A 2012-11-16 2013-11-15 Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4 MA38099B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12192987 2012-11-16
PCT/EP2013/073946 WO2014076237A1 (fr) 2012-11-16 2013-11-15 Triazolopyrazine

Publications (2)

Publication Number Publication Date
MA38099A1 true MA38099A1 (fr) 2018-01-31
MA38099B1 MA38099B1 (fr) 2018-06-29

Family

ID=47177838

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38099A MA38099B1 (fr) 2012-11-16 2013-11-15 Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4

Country Status (38)

Country Link
US (3) US9266891B2 (fr)
EP (1) EP2925761B1 (fr)
JP (1) JP5959754B2 (fr)
KR (1) KR102190087B1 (fr)
CN (2) CN107266455B (fr)
AP (1) AP2015008418A0 (fr)
AR (1) AR093515A1 (fr)
AU (1) AU2013346809B9 (fr)
BR (1) BR112015011158B1 (fr)
CA (1) CA2891193C (fr)
CL (1) CL2015001250A1 (fr)
CY (1) CY1119387T1 (fr)
DK (1) DK2925761T3 (fr)
EA (1) EA029051B1 (fr)
ES (1) ES2641465T3 (fr)
GE (1) GEP201706624B (fr)
HK (1) HK1210169A1 (fr)
HR (1) HRP20171474T1 (fr)
HU (1) HUE034467T2 (fr)
IL (1) IL238400A (fr)
LT (1) LT2925761T (fr)
MA (1) MA38099B1 (fr)
ME (1) ME02857B (fr)
MX (1) MX363587B (fr)
MY (1) MY191358A (fr)
NZ (1) NZ707203A (fr)
PE (1) PE20151023A1 (fr)
PH (1) PH12015501074B1 (fr)
PL (1) PL2925761T3 (fr)
PT (1) PT2925761T (fr)
RS (1) RS56333B1 (fr)
SG (1) SG11201503856XA (fr)
SI (1) SI2925761T1 (fr)
TN (1) TN2015000187A1 (fr)
TW (1) TWI619717B (fr)
UA (1) UA114739C2 (fr)
UY (1) UY35142A (fr)
WO (1) WO2014076237A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
US9428513B2 (en) * 2013-11-07 2016-08-30 Boehringer Ingelheim International Gmbh Triazolopyrazine
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
CN105669733A (zh) * 2016-01-29 2016-06-15 上海毕路得医药科技有限公司 一种1-甲基-1h-吡唑-3-硼酸频哪醇酯的合成方法
AU2017359288A1 (en) * 2016-11-14 2019-05-30 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer
CN109111437B (zh) * 2017-06-22 2022-03-04 中国科学院广州生物医药与健康研究院 一种苯并[d]异恶唑类化合物及其制备方法和应用
CA3070273A1 (fr) 2017-07-18 2019-01-24 Nuvation Bio Inc. Composes heterocycliques utilises en tant qu'antagonistes de l'adenosine
JP2020527593A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． １，８−ナフチリジノン化合物およびその使用
WO2019145410A1 (fr) 2018-01-25 2019-08-01 Boehringer Ingelheim International Gmbh Traitement combiné de leucémie myéloïde aiguë
JP2021522462A (ja) 2018-04-19 2021-08-30 エンバー テクノロジーズ， インコーポレイテッド アクティブ温度制御を備えた携帯型冷却器
CN108794484B (zh) * 2018-04-28 2020-04-24 北京施安泰医药技术开发有限公司 [1,2,4]三唑并[4,3-a]吡嗪衍生物、其药物组合物、制备方法和应用
EP3873474A4 (fr) 2018-10-30 2022-07-13 Nuvation Bio Inc. Composés hétérocycliques utilisés comme inhibiteurs de bet
JP7430728B2 (ja) 2019-01-11 2024-02-13 エンバー テクノロジーズ， インコーポレイテッド 能動的温度制御を備える可搬式冷却器
SG11202107810WA (en) 2019-01-18 2021-08-30 Nuvation Bio Inc Heterocyclic compounds as adenosine antagonists
CN113939291A (zh) 2019-01-18 2022-01-14 诺维逊生物股份有限公司 1,8-萘啶酮化合物及其用途
CA3143365A1 (fr) 2019-06-25 2020-12-30 Ember Technologies, Inc. Refroidisseur portable
US11162716B2 (en) 2019-06-25 2021-11-02 Ember Technologies, Inc. Portable cooler
US11668508B2 (en) 2019-06-25 2023-06-06 Ember Technologies, Inc. Portable cooler
EP3997070A4 (fr) 2019-07-02 2023-07-26 Nuvation Bio Inc. Composés hétérocycliques utilisés en tant qu'inhibiteurs de bet
CA3151320A1 (fr) * 2019-09-25 2021-04-01 Subtle Medical, Inc. Systemes et procedes pour ameliorer une irm amelioree par contraste volumetrique a faible dose
CA3152923A1 (fr) 2019-09-30 2021-04-08 Keisuke Yamamoto Agent de degradation de bet
WO2021175432A1 (fr) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Procédé d'administration d'un agent anticancéreux
JP2023521040A (ja) 2020-04-03 2023-05-23 エンバー ライフサイエンシズ， インコーポレイテッド 能動的温度制御を有する可搬式冷却器
WO2022184664A1 (fr) * 2021-03-02 2022-09-09 Boehringer Ingelheim International Gmbh Polythérapie anticancéreuse
US20230098872A1 (en) * 2021-03-26 2023-03-30 Cedilla Therapeutics, Inc. Tead inhibitors and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915968A (en) 1973-09-21 1975-10-28 Lepetit Spa Triazolopyridazines
CA2310072A1 (fr) 1997-11-11 1999-05-20 Hiroyuki Ohno Composes de pyrazine condenses
UA98297C2 (en) 2005-12-21 2012-05-10 Янссен Фармацевтика, Н.В. Triazolopyridazines as tyrosine kinase modulators
WO2008109104A1 (fr) 2007-03-07 2008-09-12 The Regents Of The University Of California Inhibiteurs bivalents de protéine kinase akt
EP2142551B1 (fr) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company Composés HÉTÉROCYCLIQUEs CONDENSÉS comme INHIBITEURS DE la 11-béta-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE I
BRPI0821676A2 (pt) 2007-12-21 2015-06-16 Astrazeneca Ab Composto, composição farmacêutica, e, processo para a preparação dos compostos.
EP2239264A4 (fr) * 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp Agent antitumoral
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
NZ599258A (en) * 2009-11-05 2014-05-30 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
WO2011089400A1 (fr) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibiteurs de la pi3 kinase
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (fr) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Inhibiteurs à bromodomaine et leurs utilisations
DE102011082013A1 (de) * 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
AR091022A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
KR20150100613A (ko) * 2012-09-28 2015-09-02 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 함유하는 약제학적 제제
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9266891B2 (en) * 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
US9199988B2 (en) 2013-03-27 2015-12-01 Boehringer Ingelheim International Gmbh Dihydroquinazolinone analogues
US9102684B2 (en) 2013-03-27 2015-08-11 Boehringer Ingelheim International Gmbh Indolinone analogues
US20150051208A1 (en) 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US9428513B2 (en) 2013-11-07 2016-08-30 Boehringer Ingelheim International Gmbh Triazolopyrazine
US9428515B2 (en) 2014-05-09 2016-08-30 Boehringer Ingelheim International Gmbh Benzimidazole derivatives

Also Published As

Publication number Publication date
CN104870448B (zh) 2017-07-07
ME02857B (fr) 2018-04-20
SI2925761T1 (sl) 2017-10-30
AR093515A1 (es) 2015-06-10
EA201500536A1 (ru) 2016-04-29
CN107266455A (zh) 2017-10-20
IL238400A (en) 2017-07-31
AP2015008418A0 (en) 2015-05-31
AU2013346809B9 (en) 2017-12-14
KR20150082314A (ko) 2015-07-15
HK1210169A1 (en) 2016-04-15
BR112015011158A2 (pt) 2017-07-11
CN107266455B (zh) 2019-08-09
SG11201503856XA (en) 2015-06-29
TW201434838A (zh) 2014-09-16
JP2015537021A (ja) 2015-12-24
RS56333B1 (sr) 2017-12-29
MX363587B (es) 2019-03-27
JP5959754B2 (ja) 2016-08-02
US10328074B2 (en) 2019-06-25
PL2925761T3 (pl) 2017-12-29
UA114739C2 (uk) 2017-07-25
AU2013346809B2 (en) 2017-09-14
HRP20171474T1 (hr) 2017-11-03
ES2641465T3 (es) 2017-11-10
EA029051B1 (ru) 2018-02-28
BR112015011158A8 (pt) 2019-10-01
PH12015501074A1 (en) 2015-08-03
LT2925761T (lt) 2017-09-11
US20140142098A1 (en) 2014-05-22
US9266891B2 (en) 2016-02-23
EP2925761B1 (fr) 2017-07-05
BR112015011158B1 (pt) 2022-05-17
DK2925761T3 (en) 2017-09-18
NZ707203A (en) 2019-10-25
EP2925761A1 (fr) 2015-10-07
CA2891193C (fr) 2021-03-23
PT2925761T (pt) 2017-09-28
GEP201706624B (en) 2017-02-10
CA2891193A1 (fr) 2014-05-22
US11077107B2 (en) 2021-08-03
IL238400A0 (en) 2015-06-30
MA38099B1 (fr) 2018-06-29
MX2015005953A (es) 2015-09-16
CL2015001250A1 (es) 2015-08-14
PE20151023A1 (es) 2015-08-01
TN2015000187A1 (en) 2016-10-03
CY1119387T1 (el) 2018-02-14
HUE034467T2 (en) 2018-02-28
US20160129001A1 (en) 2016-05-12
WO2014076237A1 (fr) 2014-05-22
TWI619717B (zh) 2018-04-01
PH12015501074B1 (en) 2015-08-03
MY191358A (en) 2022-06-19
AU2013346809A1 (en) 2015-05-07
UY35142A (es) 2014-05-30
KR102190087B1 (ko) 2020-12-11
CN104870448A (zh) 2015-08-26
US20190240219A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
MA38099A1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA38175A1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA38287B1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
TN2014000195A1 (fr) 2-thiopyrimidinones
MA35895B1 (fr) Inhibiteurs d'iap
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA38556A1 (fr) Inhibiteurs de bace1
FR2939135B1 (fr) Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA35457B1 (fr) Nouvelles formulations de pyriméthanil et leur utilisations dans le traitement des cultures
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
FR3041639B1 (fr) NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
MA34946B1 (fr) Nouvelles benzodioxolepipérazines
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
FR2968662B1 (fr) Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
MA51020B1 (fr) Composés imidazopyridiniques et leur utilisation comme médicament